Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Topical Brepocitinib in Plaque Psoriasis
NCT03850483Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of brepocitinib in plaque psoriasis (9 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Psoriasis Area and Severity Index at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03850483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850483.